FY2025 Earnings Forecast for PepGen Issued By HC Wainwright

PepGen Inc. (NASDAQ:PEPG) – HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for PepGen in a research report issued on Monday, February 24th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($2.96) for the year, down from their prior forecast of ($2.42). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s FY2026 earnings at ($2.54) EPS, FY2027 earnings at ($1.99) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.31) EPS.

A number of other equities analysts have also weighed in on PEPG. Wedbush lowered their target price on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research note on Monday, December 16th.

PepGen Trading Up 29.6 %

Shares of NASDAQ PEPG opened at $3.15 on Thursday. The firm has a market cap of $102.68 million, a P/E ratio of -1.06 and a beta of 1.53. PepGen has a 1-year low of $1.16 and a 1-year high of $19.30. The business’s 50 day moving average is $2.37 and its 200-day moving average is $5.69.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13.

Hedge Funds Weigh In On PepGen

A number of hedge funds have recently added to or reduced their stakes in PEPG. RTW Investments LP bought a new position in PepGen during the 4th quarter worth $12,102,000. Janus Henderson Group PLC increased its stake in PepGen by 331.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after acquiring an additional 1,794,641 shares during the period. Millennium Management LLC increased its stake in PepGen by 1,033.2% during the 4th quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock worth $594,000 after acquiring an additional 142,814 shares during the period. Suvretta Capital Management LLC increased its stake in PepGen by 9.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after acquiring an additional 140,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in PepGen during the 4th quarter worth $516,000. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.